Loading market dashboard
Revolution Medicines, Inc.
RVMDHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Can the drugmaker justify its valuation?
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Revolution Medicines (RVMD) moved higher in US premarket trading after fresh data added more weight to the story around daraxonrasib, its experimental pancreati
Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
REDWOOD CITY, Calif. , May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that members of Revolution Medicines' senior management team will host a webcast on Sunday, May 31 at 7:00 pm ET to discuss positive results from the Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) following presentation of the data during the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.
U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease.
U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await what they hope will be a speedy FDA approval.
Expense ratios, diversification, and sector tilts set these two small-cap ETFs apart. Explore how their strategies impact risk and long-term performance.
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects, researchers reported on Wednesday.
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.
The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution Medicines' pill for patients with previously treated pancreatic cancer, the company said on Friday.
Compare how sector allocations, cost, and diversification set these two leading small-cap ETFs apart for investors seeking broad market exposure.
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close.
Expense ratios, diversification, and recent returns reveal key differences between these two leading small-cap ETFs.
Compare how expense ratios, yield, and portfolio breadth set these two small-cap ETFs apart in risk and income profile.
Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
Investors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib. Daraxonrasib significantly extended the life of patients in a recent clinical trial.
Explore how these two small-cap ETFs differ in diversification, risk, and portfolio strategy to help refine your investment approach.
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two Phase 1/2 trials of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Data from the daraxonrasib combination cohort will be presented in a late-breaking mini-symposium, and data from the monotherapy cohort will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21, 2026.
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer
REDWOOD CITY, Calif. , April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026 in Chicago.
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago.
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT.
REDWOOD CITY, Calif. , April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC).
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Mark Goldsmith sold 120,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider owned 276,698 shares in the
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its concurrent upsized public offerings of 12,147,887 shares of its common stock at a public offering price of $142.00 per share and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 (the “notes”). The shares of common stock issued and sold in the common stock offering include 1,584,506 shares issued upon exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offerings, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, were approximately $2,225.0 million.
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public offerings of 10,563,381 shares of common stock, at a public offering price of $142.00 per share, for aggregate gross proceeds of approximately $1.5 billion, and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 (the “notes”). The offering size of the common stock offering was increased from the previously announced offering size of $750.0 million and the offering size of the note offering was increased from the previously announced offering size of $250.0 million. The issuance and sale of the common stock and the notes are scheduled to settle on April 16, 2026 and April 17, 2026, respectively, subject to customary closing conditions. Revolution Medicines also granted the underwriters of the common stock offering a 30-day option to purchase up to an additional 1,584,506 shares of common stock. The completion of the common stock offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock offering.
Revolution Medicines (RVMD) remains a 'Strong Buy' following statistically significant phase 3 RASolute 302 results for daraxonrasib in 2nd-line metastatic PDAC. Company's daraxonrasib achieved median overall survival of 13.2 months vs. 6.7 months for chemotherapy in the ITT population [p < 0.0001]. Expansion opportunities include phase 3 RASolute 303 for 1st-line PDAC and additional late-stage trials in NSCLC and adjuvant settings.
Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.
REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its intention to offer, subject to market and other conditions, $750 million of common stock and $250 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. Revolution Medicines also expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $112.5 million of common stock, and expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $37.5 million principal amount of notes solely to cover over-allotments. The completion of the common stock offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock offering.
Revolution Medicines (RVMD) has reached all-time highs following the announcement of remarkable results from the pivotal Phase 3 RASolute 302 trial. The trial d
Revolution Medicines Inc (NASDAQ:RVMD) stock is brushing off the broad market selloff this morning, last seen up 35.5% to trade at $131.35, and earlier hitting a record high of $135.81.
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential breakthrough in one of the deadliest forms of the disease. The stock climbed 38% after the opening bell, extending gains to 69% since the start of the year.
The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.
Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.
Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocks Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identified NVIDIA as a buy back in 2010 - before its 28,000% run - has just pinpointed 10 new AI... Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial.
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% versus chemotherapy.
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
SG Americas Securities LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 56.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,723 shares of the company's stock after acquiring an additional 6,009 shares during the quarter.
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.
Shares of Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) have been given a consensus rating of "Buy" by the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fifteen have given a buy recommendation and five have assigned a strong buy
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Stephen Michael Kelsey sold 4,302 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the transaction, the insider directly owned 295,398 shares in the
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) COO Margaret Horn sold 4,583 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the transaction, the chief operating officer directly owned 157,570 shares in
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 2,753 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the transaction, the chief financial officer owned 125,512 shares in the company, valued at
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.
Algert Global LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 141.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 166,315 shares of the company's stock after purchasing an additional 97,332 shares during the quarter. Algert Global LLC owned
General Atlantic L.P. acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,474,428 shares of the company's stock, valued at approximately $115,556,000. Revolution Medicines comprises about 3.5% of General Atlantic L.P.'s investment portfolio,
